Lokman Hekim University, Faculty of Medicine, Ankara Hospital, Department of Internal Diseases, Ankara, Turkey.
Altınbas University, Faculty of Medicine, Medical Park Bahcelievler Hospital, Department of Gastroenterology, Istanbul, Turkey.
Arq Gastroenterol. 2023 Jul-Sep;60(3):350-355. doi: 10.1590/S0004-2803.230302-23-51.
•In eradication treatment of H. pylori gemifloxacin containing triple treatment regimen was as effective as bismuth containing quadruple treatment. •Drug adverse effects were fewer and milder in the gemifloxacin group. •Since treatment period was shorter and pills to be taken were fewer compared to quadruple treatment, patient compliance was significantly higher in the gemifloxacin group. Background - After eradication of Helicobacter pylori (H. pylori) chronic gastritis will resolve, complications due to H. pylori infection and recurrence of infection will be prevented. Objective - To determine efficacy and safety of gemifloxacin containing treatment regimen in first line treatment of H. pylori with comparison to bismuth containing quadruple therapy. Methods - This retrospective study was conducted in a tertiary care university hospital between January 2018 and January 2021 with 410 participants who were diagnosed to have H. pylori infection with biopsies obtained during upper gastrointestinal system endoscopy. Patients were distributed into two groups according to their first-line treatment regimens. First group patients were treated with amoxicillin, gemifloxacin and pantoprazole and second group patients were treated with amoxicillin, metronidazole, bismuth subcitrate and pantoprazole for seven days. Results - Intention to treat and per protocol ratios for gemifloxacin containing regimen were 90.0% and 91.2%, while quadruple treatment has these ratios as 91.7% and 93.8% respectively. Treatment success rate in both regimens were similar. But adverse effects were lower and patient compliance were better in patients who had gemifloxacin containing treatment (P<0.001). Conclusion - Gemifloxacin containing treatment regimen is as effective as bismuth containing quadruple treatment regimen for H. pylori infection and patient compliance is better in this group. Gemifloxacin containing treatment regimens may be novel and effective alternatives for eradication of H. pylori infection.
• 在幽门螺杆菌的根治治疗中，含加替沙星的三联疗法与含铋的四联疗法同样有效。 • 加替沙星组的药物不良反应更少且更轻微。 • 由于治疗期比四联疗法短，服用的药丸也更少，因此加替沙星组的患者依从性明显更高。 背景 - 根除幽门螺杆菌（H. pylori）后，慢性胃炎将得到缓解，可预防因 H. pylori 感染引起的并发症和感染复发。 目的 - 与铋四联疗法相比，确定含加替沙星的治疗方案在治疗幽门螺杆菌的一线治疗中的疗效和安全性。 方法 - 这项回顾性研究于 2018 年 1 月至 2021 年 1 月在一家三级护理大学医院进行，共有 410 名经上消化道内镜活检诊断为幽门螺杆菌感染的患者参加。根据他们的一线治疗方案，将患者分为两组。第一组患者接受阿莫西林、加替沙星和泮托拉唑治疗，第二组患者接受阿莫西林、甲硝唑、柠檬酸铋和泮托拉唑治疗，疗程为 7 天。 结果 - 意向治疗和方案符合率对于含加替沙星方案分别为 90.0%和 91.2%，而四联治疗的这些比率分别为 91.7%和 93.8%。两种方案的治疗成功率相似。但在接受含加替沙星治疗的患者中，不良反应更低，患者依从性更好（P<0.001）。 结论 - 含加替沙星的治疗方案与含铋的四联疗法治疗幽门螺杆菌感染同样有效，且该组患者的依从性更好。含加替沙星的治疗方案可能是治疗幽门螺杆菌感染的新的有效替代方案。
